1 Presentation on Measles Group 1

download 1 Presentation on Measles Group 1

of 27

Transcript of 1 Presentation on Measles Group 1

  • 8/3/2019 1 Presentation on Measles Group 1

    1/27

    Measles SurveillanceMeasles Surveillance

    Group 1

    1. Dr. Binay Kr.

    2. Dr. Om Prakash3. Dr. Parvez

    4. Dr. O Ramesh Singh

    5. Dr. Sunep

    6. Dr. AdityaPGDPHM- 12 IIPHD

  • 8/3/2019 1 Presentation on Measles Group 1

    2/27

    OUTLINES

    y Background

    y Case definitions

    y Laboratory criteria for diagnosis

    y

    Type of surveillancey Selection & training

    y Flow chart for distribution of forms &

    kitsy Data flow chart

    y Action

  • 8/3/2019 1 Presentation on Measles Group 1

    3/27

  • 8/3/2019 1 Presentation on Measles Group 1

    4/27

    In 1998 it is estimated that there were

    approximately one million deaths from measles

    MORTALITY

    PRE-VACCINE ERA

    1998

    MORBIDITY

    0

    1

    2

    3

    4

    5

    6

    7

    Millions

    0

    20

    40

    60

    80

    100

    120

    Millions

    PRE-VACCINE ERA

    1998

    WHO unpublished data

    63% 83%

    In other words,

    the measles virus killed ..

    2,410 children each day

    100 children each hour

    . 150 children died

    during the time elapsed

    by the end of this

    presentation

  • 8/3/2019 1 Presentation on Measles Group 1

    5/27

    Diphtheria

    0.2%

    Pertussis

    16%

    Neonatal

    Tetanus

    12%

    Yellow Fever2%

    Measles

    48%(777,000

    Deaths)

    Hib

    22%

    Causes of 1.6 million vaccineCauses of 1.6 million vaccine--preventable deathspreventable deathsamongamong childrenchildren, 2000, 2000

    Source: WHO/IP

    MEASLES: A leading cause of childhood deaths

  • 8/3/2019 1 Presentation on Measles Group 1

    6/27

    Case DefinitionsCase DefinitionsFor sub CentersFor sub Centers

    A child with -

    generalized maculopapular rash,

    fever, and

    with one or more of the following:

    cough,

    coryza - sneezing, nasal congestion,

    and nasal discharge

  • 8/3/2019 1 Presentation on Measles Group 1

    7/27

    Maculopapular

    RashFever +

    Cough OR

    Coryza (runny nose) OR

    Conjunctivitis (red eyes)+

    uspected Measlesuspected Measles

    linicallinical Case DefinitionCase Definition

    OR

    Clinician

    Suspects

    Measles

  • 8/3/2019 1 Presentation on Measles Group 1

    8/27

    Case DefinitionsCase DefinitionsFor MOs at CHC/PHC/DHFor MOs at CHC/PHC/DH

    Measles is characterized by a

    generalized maculopapular rash,

    fever, and

    With one or more of the following:

    cough,

    coryza

    Conjunctivitis,photophobia,

    Kopliks spots - bluish-white specks on arose-red background appearing on thebuccal mucosa usually opposite themolars.

  • 8/3/2019 1 Presentation on Measles Group 1

    9/27

  • 8/3/2019 1 Presentation on Measles Group 1

    10/27

    Measles Case Definition To AssistMeasles Case Definition To Assist

    Communities inCommunities in

    Notifying Health FacilitiesNotifying Health Facilities

    ANY PERSONwith

    FEVER and RASH

  • 8/3/2019 1 Presentation on Measles Group 1

    11/27

    Key Information to Collect on SuspectedKey Information to Collect on Suspected

    Measles CasesMeasles Cases

    Person

    Age

    Vaccination status

    Lab data

    Time

    Date of rash onset

    PlaceResidence at onset

    Potential exposures (places, persons)

  • 8/3/2019 1 Presentation on Measles Group 1

    12/27

    Improved RoutineImproved Routine

    ImmunizationImmunization

    StrengthenStrengthen

    measles surveillancemeasles surveillance

    SupplementalSupplemental

    measles immunizationmeasles immunization

    Improved caseImproved case

    managementmanagement

    Vitamin AVitamin A

    supplementationsupplementation

    Measles Mortality Reduction StrategiesMeasles Mortality Reduction Strategies

  • 8/3/2019 1 Presentation on Measles Group 1

    13/27

    LaboratoryLaboratory Criteria for DiagnosisCriteria for Diagnosis

    Significant rise in serum measles

    immunoglobulin G (IgG)antibody level by

    any standard serologic assay

    Positive serologic test for measlesimmunoglobulin M (IgM)antibody.

  • 8/3/2019 1 Presentation on Measles Group 1

    14/27

    Rash Illness

    Rubella

    Roseola Infantum

    Other Viral Exanthems

    Meningococcemia

    Mononucleosis

    Toxoplasmosis

    Dengue

    Kawasaki

    Measles

    Scarlet Fever

  • 8/3/2019 1 Presentation on Measles Group 1

    15/27

    Type of surveillance for measlesType of surveillance for measles

    Active surveillance

    High no of case

    Highly infectious

    High morbidity and mortality

    Easily preventable

    Main objective is sustainable reduction in morbidity& mortality due to measles.

  • 8/3/2019 1 Presentation on Measles Group 1

    16/27

    Responsible persons forreportingy Reporting unit

    Medical Officers

    Hospitals: inpatient and outpatient

    clinics.

    Medical Officers/SN/ANM/Vaccinators

    CHC/PHC/SC

    y Information unit

    Private clinics/hospitals/nursing homes

  • 8/3/2019 1 Presentation on Measles Group 1

    17/27

    Selection and training

    Medical Officers at District level, by DIO

    MOs and Private practitioners at district level

    will be trained at the district level

    All the ANM, Field staffs and ASHAs- to be

    trained at CHC/PHC level

    All Private practitioners, at block level andbelow, to be trained at CHC/PHC level

  • 8/3/2019 1 Presentation on Measles Group 1

    18/27

    What should health care provider do whenWhat should health care provider do when

    she/he suspects measles?she/he suspects measles?

    y Notify case

    y Complete case investigation form

    y Collect blood sample

    y Manage case (Vitamin A, supportivetreatment, etc.)

  • 8/3/2019 1 Presentation on Measles Group 1

    19/27

  • 8/3/2019 1 Presentation on Measles Group 1

    20/27

    Flow chart for forms & kitsFlow chart for forms & kits

    CMO

    DIO

    DH/DS

    MO i/c -CHC/PHC/SC

    Privatehosp/clinic

    ASHA

  • 8/3/2019 1 Presentation on Measles Group 1

    21/27

    FLOW OF DATA

    State

    District CMO

    District

    Immunization

    Officer

    CHCMO & SN

    District

    Hospitals

    MS/DS

    PHCMO

    Private

    Hospitals/

    Nursing

    homes/Quacks

    MO & SN

    Sub Centre

    ANM

    ASHA

  • 8/3/2019 1 Presentation on Measles Group 1

    22/27

    tools for collection of data andtools for collection of data and

    samplessamples

  • 8/3/2019 1 Presentation on Measles Group 1

    23/27

    Action/ Implement

    Activities will includey strengthening routine immunization

    y raising awareness of vaccination

    y effective case management

    The response should take place before an

    outbreak occurs.

    In case of a confirmed measles outbreak, DIO will form

    an outbreak response team at district level consisting of a

    Medical Officer, Microbiologist & epidemiologist.

  • 8/3/2019 1 Presentation on Measles Group 1

    24/27

    Outbreak ResponseOutbreak Response

    1. Case notification

    2. Case verification

    3. Field investigation4. Management

    5. Post outbreak activities

  • 8/3/2019 1 Presentation on Measles Group 1

    25/27

  • 8/3/2019 1 Presentation on Measles Group 1

    26/27

  • 8/3/2019 1 Presentation on Measles Group 1

    27/27